SZDB: A Database for Schizophrenia Genetic Research

Schizophrenia Bulletin

Volumn 43, Issue 2, 2017, Pages 459-471

  Wu, Yong ^a,b   Yao, Yong Gang ^a,b,c   Luo, Xiong Jian ^a,b  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Shenzhen Fundamental Research Institutions   (China)

Author keywords

database; gene expression; genetic study; integrative analysis; schizophrenia

Indexed keywords

GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MEDICAL RESEARCH; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMEDICAL RESEARCH; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION MAPS; SCHIZOPHRENIA;

EID: 85026314011     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw102     Document Type: Article

References (91)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
2. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr Res. 2008;100:4 19.
3. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2008.
4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279 293.
5. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122 1129.
6. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21:2017 2028.
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209 1223.
8. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68:e04.
9. Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia: etiology and course. Annu Rev Psychol. 2004;55:401 430.
10. Buka SL, Tsuang MT, Lipsitt LP. Pregnancy/delivery complications and psychiatric diagnosis. A prospective study. Arch Gen Psychiatry. 1993;50:151 156.
11. Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M. Obstetric complications and the risk of schizophrenia: A longitudinal study of a national birth cohort. Arch Gen Psychiatry. 1999;56:234 240.
12. Barr CE, Mednick SA, Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch Gen Psychiatry. 1990;47:869 874.
13. Brown AS, Cohen P, Harkavy-Friedman J, et al. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry. 2001;49:473 486.
14. van Os J, Selten JP. Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. Br J Psychiatry. 1998;172:324 326.
15. Quenstedt M, Parshall A. Prenatal exposure to maternal stress and subsequent schizophrenia. Br J Psychiatry. 1998;173:183.
16. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-Analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187 1192.
17. Sullivan PF, Daly MJ, O Donovan M. Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat Rev Genet. 2012;13:537 551.
18. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-Analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003;73:34 48.
19. Ng MY, Levinson DF, Faraone SV, et al. Meta-Analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry. 2009;14:774 785.
20. Allen NC, Bagade S, McQueen MB, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat Genet. 2008;40:827 834.
21. O Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40:1053 1055.
22. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748 752.
23. Ripke S, O Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150 1159.
24. Ikeda M, Aleksic B, Kinoshita Y, et al. Genome-wide association study of schizophrenia in a Japanese population. Biol Psychiatry. 2011;69:472 478.
25. Hamshere ML, Walters JT, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2013;18:708 712.
26. Rietschel M, Mattheisen M, Degenhardt F, et al. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol Psychiatry. 2012;17:906 917.
27. Irish Schizophrenia Genomics Consortium & Wellcome Trust Case Control Consortium. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry. 2012;72:620 628.
28. Shi J, Levinson DF, Duan J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460:753 757.
29. Shi Y, Li Z, Xu Q, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet. 2011;43:1224 1227.
30. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744 747.
31. Li J, Zhou G, Ji W, et al. Common variants in the BCL9 gene conferring risk of schizophrenia. Arch Gen Psychiatry. 2011;68:232 240.
32. Steinberg S, de Jong S, Andreassen OA, et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet. 2011;20:4076 4081.
33. Wong EH, So HC, Li M, et al. Common variants on Xq28 conferring risk of schizophrenia in Han Chinese. Schizophr Bull. 2014;40:777 786.
34. Yue WH, Wang HF, Sun LD, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet. 2011;43:1228 1231.
35. Lencz T, Guha S, Liu C, et al. Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun. 2013;4:2739.
36. Schizophrenia Working Group of the Psychiatric Genomics Consortium*. Biological insights from 108 schizophreniaassociated genetic loci. Nature. 2014;511:421 427.
37. Stefansson H, Rujescu D, Cichon S, et al.; GROUP. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455:232 236.
38. The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455:237 241.
39. Xu B, Roos JL, Levy S, et al. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 2008;40:880 885.
40. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539 543.
41. Malhotra D, McCarthy S, Michaelson JJ, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011;72:951 963.
42. Ayalew M, Le-Niculescu H, Levey DF, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012;17:887 905.
43. Horvath S, Mirnics K. Schizophrenia as a disorder of molecular pathways. Biol Psychiatry. 2015;77:22 28.
44. Hall J, Trent S, Thomas KL, O Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry. 2015;77:52 58.
45. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336 2337.
46. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790 1797.
47. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57 74.
48. Xie D, Boyle AP, Wu L, et al. Dynamic trans-Acting factor colocalization in human cells. Cell. 2013;155:713 724.
49. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31:3812 3814.
50. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073 1081.
51. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248 249.
52. Luo XJ, Mattheisen M, Li M, et al. Systematic Integration of Brain eQTL and GWAS Identifies ZNF323 as a Novel Schizophrenia Risk Gene and Suggests Recent Positive Selection Based on Compensatory Advantage on Pulmonary Function. Schizophr Bull. 2015;41:1294 1308.
53. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185 190.
54. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179 184.
55. Jia P, Sun J, Guo AY, Zhao Z. SZGR: A comprehensive schizophrenia gene resource. Mol Psychiatry. 2010;15:453 462.
56. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z. Candidate genes for schizophrenia: A survey of association studies and gene ranking. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1173 1181.
57. Luo X, Huang L, Han L, et al. Systematic prioritization and integrative analysis of copy number variations in schizophrenia reveal key schizophrenia susceptibility genes. Schizophr Bull. 2014;40:1285 1299.
58. He X, Fuller CK, Song Y, et al. Sherlock: detecting genedisease associations by matching patterns of expression QTL and GWAS. Am J Hum Genet. 2013;92:667 680.
59. Lanz TA, Joshi JJ, Reinhart V, et al. STEP levels are unchanged in pre-frontal cortex and associative striatum in post-mortem human brain samples from subjects with schizophrenia, bipolar disorder and major depressive disorder. PLoS One. 2015;10:e0121744.
60. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241 253.
61. Narayan S, Tang B, Head SR, et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008;1239:235 248.
62. Chen C, Cheng L, Grennan K, et al. Two gene co-expression modules differentiate psychotics and controls. Mol Psychiatry. 2013;18:1308 1314.
63. de Baumont A, Maschietto M, Lima L, et al. Innate immune response is differentially dysregulated between bipolar disease and schizophrenia. Schizophr Res. 2015;161:215 221.
64. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18:206 214.
65. Lamparter D, Marbach D, Rueedi R, Kutalik Z, Bergmann S. Fast and rigorous computation of gene and pathway scores from snp-based summary statistics. PLoS Comput Biol. 2016;12:e1004714.
66. Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71:255 264.
67. Montano C, Taub MA, Jaffe A, et al. Association of DNA methylation differences with schizophrenia in an epigenomewide association study. JAMA Psychiatry. 2016;73:506 514.
68. Hannon E, Spiers H, Viana J, et al. Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. Nat Neurosci. 2016;19:48 54.
69. Myers AJ, Gibbs JR, Webster JA, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39:1494 1499.
70. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559 575.
71. BrainSpan. BrainSpan: Atlas of the Developing Human Brain [Internet]. 2013. http://www.brainspan.org. Accessed April 28, 2015.
72. Willsey AJ, Sanders SJ, Li M, et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. 2013;155:997 1007.
73. Gulsuner S, Walsh T, Watts AC, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013;154:518 529.
74. Colantuoni C, Lipska BK, Ye T, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature. 2011;478:519 523.
75. Gilman SR, Chang J, Xu B, et al. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci. 2012;15:1723 1728.
76. Oti M, Brunner HG. The modular nature of genetic diseases. Clin Genet. 2007;71:1 11.
77. Jia P, Zhao Z. Network.assisted analysis to prioritize GWAS results: principles, methods and perspectives. Hum Genet. 2014;133:125 138.
78. Luo X, Huang L, Jia P, et al. Protein-protein interaction and pathway analyses of top schizophrenia genes reveal schizophrenia susceptibility genes converge on common molecular networks and enrichment of nucleosome (chromatin) assembly genes in schizophrenia susceptibility loci. Schizophr Bull. 2014;40:39 49.
79. Luo XJ, Huang L, Li M, Gan L. Protein-protein interaction analysis reveals common molecular processes/pathways that contribute to risk of schizophrenia. Schizophr Res. 2013;143:390 392.
80. Lage K, Karlberg EO, Storling ZM, et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol. 2007;25:309 316.
81. Lage K, Hansen NT, Karlberg EO, et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A. 2008;105:20870 20875.
82. Parikshak NN, Luo R, Zhang A, et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell. 2013;155:1008 1021.
83. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9 26.
84. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091 D1097.
85. Kang HJ, Kawasawa YI, Cheng F, et al. Spatio-Temporal transcriptome of the human brain. Nature. 2011;478:483 489.
86. Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35:W169 W175.
87. Huang DW, Sherman BT, Tan Q, et al. The DAVID Gene Functional Classification Tool: A novel biological modulecentric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8:R183.
88. Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopamine D2 receptor/beta-Arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008;105:13656 13661.
89. Fregeau MO, Carrier M, Guillemette G. Mechanism of dopamine D2 receptor-induced Ca(2+) release in PC-12 cells. Cell Signal. 2013;25:2871 2877.
90. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206 1227.
91. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515 531.